Mural Oncology (MURA)
NASDAQ: MURA
· Real-Time Price · USD
2.63
0.01 (0.38%)
At close: Apr 30, 2025, 3:59 PM
2.68
2.10%
After-hours: Apr 30, 2025, 04:40 PM EDT
Company Description
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer.
The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs.
The company was incorporated in 2017 and is based in Dublin, Ireland.
As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.
Mural Oncology
| Country | IE |
| IPO Date | Nov 16, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 116 |
| CEO | Caroline J. Loew Ph.D. |
Contact Details
Address: 10 Earlsfort Terrace Dublin, IE | |
| Website | https://www.muraloncology.com |
Stock Details
| Ticker Symbol | MURA |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001971543 |
| CUSIP Number | n/a |
| ISIN Number | IE000LK2BOB4 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Caroline J. Loew Ph.D. | President, Chief Executive Officer & Director |
| Adam D. Cutler B.A. | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer |
| Maiken Keson-Brookes | Chief Legal Officer |
| Dr. Vicki L. Goodman M.D. | Chief Medical Officer |
| Justin Levine | Head of Human Resources & Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Filing |
| Apr 28, 2025 | DEF 14A | Filing |
| Apr 16, 2025 | SCHEDULE 13G | Filing |
| Apr 15, 2025 | 8-K | Current Report |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 11, 2025 | 8-K | Current Report |
| Mar 11, 2025 | 424B5 | Filing |
| Mar 11, 2025 | S-8 | Filing |
| Mar 11, 2025 | 10-K | Annual Report |